HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

phospholipid emulsion soybean oil (Intralipid)

Subscribe to New Research on phospholipid emulsion soybean oil

Also Known As:

Intralipid; soybean oil, phospholipid emulsion; Clintec brand of soybean oil, phospholipid emulsion; Hospira brand of soybean oil, phospholipid emulsion; Intrafat; Liposyn III; Nihon brand of soybean oil, phospholipid emulsion; Travamulsion

Networked: 393 relevant articles (24 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Liu, Jin: 5 articles (02/2014 - 07/2007)
2.	Segal, Esther: 5 articles (07/2012 - 12/2003)
3.	Giacca, Adria: 4 articles (11/2015 - 04/2006)
4.	Sionov, Edward: 4 articles (08/2006 - 12/2003)
5.	Eghbali, Mansoureh: 3 articles (08/2015 - 08/2011)
6.	Rahman, Siamak: 3 articles (08/2015 - 08/2011)
7.	Umar, Soban: 3 articles (08/2015 - 08/2011)
8.	Cave, Grant: 3 articles (04/2009 - 04/2005)
9.	Jensen, Christine B: 3 articles (03/2004 - 06/2003)
10.	Madsbad, Sten: 3 articles (03/2004 - 06/2003)

Related Diseases

1.	Aspergillosis 02/01/2004 - "Treatment of murine systemic aspergillosis with polyene-intralipid admixtures." 08/01/2006 - "The objective of this study was to evaluate the efficacy of combination treatment consisting of the polyene amphotericin B (AMB) or amphotericin B-intralipid admixture (AMB-IL) and the echinocandin caspofungin (CAS) in experimental murine systemic aspergillosis. " 08/01/2006 - "Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis." 02/01/2004 - "The objective of this research was the evaluation of the activity of admixtures of amphotericin B (AMB)--intralipid (AMB-IL) and nystatin (Ny)--intralipid (Ny-IL) against experimental systemic aspergillosis in immunocompromised mice. " 09/01/2005 - "In view of the poor therapy outcomes of invasive aspergillosis, the objective of this study was to evaluate the efficacy of combination treatment consisting of the polyene amphotericin-B-intralipid, the echinocandin caspofungin and granulocyte-colony stimulating factor (G-CSF) in experimental murine systemic aspergillosis. "
2.	Infection 10/01/2011 - "In summary, the Intralipid formulation of NYT can be administered parenterally and is effective against systemic experimental Candida infection." 07/01/1982 - "In vivo, intralipid inhibited murine ADCC and completely nullified the protection against lethal infection with HSV in neonatal mice afforded by the administration of human leukocytes and antibody. " 05/01/1997 - "In a pilot crossover trial, aqueous AmB followed by a new preparation of a mixture of AmB with 20% intralipid (AmB-IL) was administered to 10 immunocompromised patients for systemic fungal infections caused by Candida species. " 11/01/1999 - "To determine whether Intralipid affected infection, New Zealand white rabbits were injected intravenously with S. " 08/01/1985 - "Systemic infection with Malassezia furfur was first reported in 1981 as a specific complication of Intralipid therapy in a neonate. "
3.	Cryptococcal Meningitis 04/01/2007 - "Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). " 01/01/1996 - "Use of intralipid as a vehicle for amphotericin B in the treatment of cryptococcal meningitis in a renal transplant recipient." 07/01/1996 - "We determined the safety and efficacy of deoxycholate-amphotericin B (d-AmB) mixed with Intralipid (IL) as the initial treatment of AIDS-associated cryptococcal meningitis in a phase II, multicentre, non-comparative open study, assessing two dosages of ILd-AmB: 1 mg/kg (group A, n = 9) and 1.5 mg/kg (group B, n = 6). " 09/01/1996 - "We conducted a randomized, open-labeled clinical trial to compare the tolerability and efficacy of amphotericin B deoxycholate, prepared in 5% dextrose or Intralipid (Kabi Pharmacia, Saint-Quentin-en-Yvelines, France), in the treatment of AIDS-associated cryptococcal meningitis in Burundi. " 09/01/1996 - "Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis."
4.	Acquired Immunodeficiency Syndrome (AIDS) 04/01/2007 - "Intralipid (AmB-IL), in 37 AIDS patients with cryptococcal meningitis (CM). " 07/01/1996 - "We determined the safety and efficacy of deoxycholate-amphotericin B (d-AmB) mixed with Intralipid (IL) as the initial treatment of AIDS-associated cryptococcal meningitis in a phase II, multicentre, non-comparative open study, assessing two dosages of ILd-AmB: 1 mg/kg (group A, n = 9) and 1.5 mg/kg (group B, n = 6). " 09/01/1996 - "We conducted a randomized, open-labeled clinical trial to compare the tolerability and efficacy of amphotericin B deoxycholate, prepared in 5% dextrose or Intralipid (Kabi Pharmacia, Saint-Quentin-en-Yvelines, France), in the treatment of AIDS-associated cryptococcal meningitis in Burundi. " 09/01/1996 - "Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis." 07/01/1998 - "To evaluate the efficacy and safety of Amphotericin B dissolved in dextrose (Amb) or in a lipid emulsion (Intralipid, Amb-IL) in AIDS patients with cryptococcal meningitis, we conducted a retrospective study in 30 AIDS patients with cryptococcal meningitis. "
5.	Ischemia 01/01/2014 - "Rat were treated with intravenous 8% EIso with 1, 2 or 4 ml/kg, or 30% intralipid with 2 ml/kg for 30 min before ischemia, respectively. " 08/01/2011 - "In vivo rat hearts or isolated Langendorff-perfused mouse hearts were subjected to ischemia followed by reperfusion with Intralipid (1% in ex vivo and one bolus of 20% in in vivo) or vehicle. " 04/01/2008 - "Intralipid administered before or after ischemia can decrease the level of CK, LDH and IS during reperfusion in isolated rat hearts. " 04/01/2008 - "Preconditioning of hearts in myocardial preconditioning (I-preC group) consisted of 15 minutes of intralipid followed by 15 minutes of wash out before ischemia for 40 minutes and reperfusion for 120 minutes. " 04/01/2008 - "To investigate whether intralipid could protect perfused hearts of rats against ischemia/reperfusion (I/R) injury when it was administered before (preconditioning) or after the adverse ischemic event (postconditioning), in order to ascertain if intralipid would be a novel therapeutic strategy for myocardial I/R injury. "

Related Drugs and Biologics

1.	Amphotericin B (Amphotericin)
2.	Granulocyte Colony-Stimulating Factor (G-CSF)
3.	caspofungin (Cancidas)
4.	Deoxycholic Acid (Sodium Deoxycholate)
5.	Glucose (Dextrose)
6.	Propofol (Diprivan)
7.	Propranolol (Inderal)
8.	Nystatin (Mycostatin)
9.	Phosphotransferases (Kinase)
10.	liposomal amphotericin B

Related Therapies and Procedures

1.	Parenteral Nutrition
2.	Total Parenteral Nutrition
3.	Pancreaticoduodenectomy
4.	Surgical Portacaval Shunt (Portacaval Anastomosis)
5.	Oral Administration